Back to search results

Pilot Study of Vitamin A and Nicotinamide for Skin Cancer in Kidney Transplant Recipients

This pilot study is testing if taking Vitamin A (1,000 μg retinyl palmitate) and Nicotinamide (500 mg NAM, a form of vitamin B3) is safe and possible for kidney transplant recipients who have a history of skin cancer. You might be able to join if you are 18 or older, have had at least two skin cancers (squamous cell carcinomas) in the past two years, or have had many benign or pre-cancerous skin lesions treated. The study will measure changes in your blood levels of Vitamin A and Nicotinamide after 6 months to see if the treatments are being absorbed. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 30 participants. It involves taking either Vitamin A, Nicotinamide, or an identical placebo pill twice a day.
What's involved
You would take study pills twice a day for 6 months. Your blood Vitamin A and Nicotinamide levels will be measured at 6 months.
Compensation
Not stated in the trial record.
Follow-up
Your blood levels will be measured at 6 months, which is the primary endpoint for this study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05702398

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Recruiting
EARLY_PHASE1Ages 18+InterventionalBasic science
Rhode Island Hospital
~30 participants
Updated 2026-03-20 on ClinicalTrials.gov
What's tested:Vitamin ANicotinamideOther: Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change of Blood Vitamin A and Nicotinamide Levels
Measured over 6 months

Conditions

Skin Cancer
Kidney Transplant Recipients

Explore related trials

Kidney TransplantationMalignant Skin Neoplasm

Where it's being run

1 sites across 1 states
Rhode Island1

Who to contact

Eunyoung Cho, ScD
[email protected]
401-863-5895
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years old or greater;
Either History of 2 or more histologically confirmed invasive cutaneous SCCs in the past 2 years or
At least one previously billed Healthcare Common Procedure Coding System code 17004 (destruction of 15 or more benign or premalignant lesions of the integumentary system);
Understands, reads, and writes English proficiently.

Exclusion

Liver disease;
Active peptic ulcer disease;
Recent myocardial infarction;
Hypotension;
Internal malignancy within past 5 years;
Renal impairment with eGFR\<15 mL/min/1.73 m2;
Being unable for follow up due to social reasons;
Gorlin's syndrome or other genetic skin cancer syndrome;
Huge number of current skin cancers;
Metastatic SCC or invasive melanoma within the past 5 years;
Pregnancy or lactation;
Need for ongoing carbamazepine use (which could have a possible interaction with NAM);
Use of acitretin or other oral retinoids within the past 6 months;
Use of supplemental NAM, niacin, vitamin A, or beta carotene within the past 6 months;
Field treatment for actinic keratoses (AKs) within the previous 4 weeks;
Use of topical steroids.

What this trial measures

  • Change of Blood Vitamin A and Nicotinamide Levels6 months